Coronavirus impact: ArcelorMittal Nippon Steel India cuts production, Tata Steel to follow suit

JSW Steel, SAIL and RINL have also cut production. Tata Steel is expected to make an announcement soon

Prince Mathews Thomas

March 28, 2020 / 11:42 AM IST

live

bselive
nselive

Volume

Todays L/H

ArcelorMittal Nippon Steel India (AMNS) has cut its production to adjust to a demand slump from key clients in auto and construction sectors.

The company is the fourth steelmaker in India after JSW Steel, SAIL and RINL, that has adjusted its production, as economic activity has come to a near standstill amidst a lockdown to limit spread of the coronavirus (COVID-19).

While a AMNS spokesperson confirmed the step, he declined to share further details. But executives from the industry said that as with all steel companies, the cut will be 'substantial' in AMNS too.

"Construction has come to a standstill amidst the lockdown and almost every auto company has shut factories. There is no point in steelmakers continuing to make steel and piling up inventories," said a senior executive from the sector.

Construction, real estate and auto are the biggest consumers of steel.

COVID-19 Vaccine

Frequently Asked Questions

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

Show

Prince Mathews Thomas heads the corporate bureau of Moneycontrol. He has been covering the business world for 16 years, having worked in The Hindu Business Line, Forbes India, Dow Jones Newswires, The Economic Times, Business Standard and The Week. A Chevening scholar, Prince has also authored The Consolidators, a book on second generation entrepreneurs.

TAGS: #Business #Companies #coronavirus #Covid-19

first published: Mar 28, 2020 11:42 am